ADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast Cancer
CHICAGO — First-line trastuzumab deruxtecan (T-DXd) combined with pertuzumab (Perjeta) improved progression-free survival (PFS) in HER2-positive locally advanced or metastatic breast cancer, according to the DESTINY-Breast09 trial. In the phase III study after a median of follow-up of 29 months, patients randomized to T-DXd plus pertuzumab had a median PFS by blinded independent central review […]
Raludotatug Deruxtecan Promising in Platinum-Resistant Advanced Ovarian Cancer
SAN DIEGO — Treatment with raludotatug deruxtecan (R-DXd) led to an “exciting” response rate among patients with heavily pretreated, platinum-resistant advanced ovarian cancer, according to an early-phase trial. In a subgroup analysis of the first-in-human phase I study, there was one complete response and 17 partial responses among 37 evaluable patients treated with R-DXd, an […]